As we discussed earlier, Abbott Laboratories’ (ABT) vascular products include a broad line of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. These products are manufactured and marketed worldwide. This segment contributed ~$2.99 billion, or ~14.75%, of the total revenue in 2014. It contributed ~$3 billion, or ~15.30%, of the total revenue in 2013. The key products in this segment are:
- drug-eluting coronary bioresorbable vascular scaffolds
- coronary metallic stents
- coronary balloon dilatation products
- vessel closure devices
- carotid and vascular stent systems
The key products for this segment include Xience—a brand of coronary stent systems, Multi-Link—a brand of coronary metallic stents, Trek and Voyager coronary balloon dilatation products, MitraClip valve repair system, Elite and Asahi coronary guidewires, Supera peripheral vascular stent system, StartClose and Perclose vessel closure devices, and Acculink and Xact carotid stent systems.
All of these stents are tube-like devices placed in the patient’s body in order to create a passage between two hollow spaces. These stents have different types like drug-eluting stents, bioresorbable stents, general bare-metal stents, and many more.
Over the last three years, the company has continued to develop its worldwide markets for Xience drug-eluting stents. It also launched Xience Alpine in 4Q14. It’s the only product in the US markets with an indication to treat chronic total inclusions.
For the vascular segment, research is carried out to evaluate the feasibility and commercial viability for a specific technology. Once the feasibility and commercial viability are justified, the development process starts. The recent developments in R&D (research and development) including products launched and in the pipeline are:
- Xience Alpine – a drug-eluting stent that received FDA (U.S. Food and Drug Administration) approval in September 2014
- Absorb – a drug eluting BVS (bioresorbable vascular scaffold) device that’s under clinical trials for regulatory approval in the US and China. The company is also working to develop future generations of BVS technologies.
- Supera is a self-expanding nitinol stent system. It was acquired as part of the acquisition of IDEV Technologies in 2013. Abbott is working to develop Supera’s size matrix and next generation delivery systems.
Other companies like Boston Scientific (BSX), Johnson & Johnson (JNJ), and Medtronic (MDT) compete with Abbott on different vascular products. The Health Care Select Sector SPDR ETF (XLV) has invested ~2.30% in Abbott.